See more : B. Riley Financial, Inc. – 6.75 (RILYO) Income Statement Analysis – Financial Results
Complete financial analysis of Bellerophon Therapeutics, Inc. (BLPH) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Bellerophon Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Fine-Line Circuits Limited (FINELINE.BO) Income Statement Analysis – Financial Results
- Public Joint Stock Company Gazprom Neft (SIBN.ME) Income Statement Analysis – Financial Results
- NewAge, Inc. (NBEV) Income Statement Analysis – Financial Results
- Nurosene Health Inc. (MEND.CN) Income Statement Analysis – Financial Results
- Paramount Resources Ltd. (PRMRF) Income Statement Analysis – Financial Results
Bellerophon Therapeutics, Inc. (BLPH)
About Bellerophon Therapeutics, Inc.
Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its product includes INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension. The company engages in the development of INOpulse that is in Phase 3 clinical trial for the treatment of pulmonary hypertension associated with fibrotic interstitial lung disease; which has completed Phase 2a clinical trial for pulmonary hypertension associated with chronic obstructive pulmonary disease; and that has completed Phase 2 dose escalation stage for pulmonary hypertension associated with sarcoidosis, as well as for chronic thromboembolic pulmonary hypertension and pulmonary hypertension associated with pulmonary edema from high altitude sickness. The company was formerly known as Ikaria Development LLC and changed its name to Bellerophon Therapeutics, Inc. in January 2014. Bellerophon Therapeutics, Inc. was founded in 2009 and is headquartered in Warren, New Jersey.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 65.00K | 102.00K | 147.00K | 348.00K | 362.00K | 373.00K | 400.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -65.00K | -102.00K | -147.00K | -348.00K | -362.00K | -373.00K | -400.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 16.36M | 13.02M | 17.89M | 11.03M | 20.26M | 17.85M | 16.65M | 33.37M | 45.98M | 52.99M | 38.73M |
| General & Administrative | 6.02M | 7.15M | 8.39M | 6.44M | 7.62M | 6.75M | 7.11M | 14.87M | 0.00 | 9.01M | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 6.02M | 7.15M | 8.39M | 6.44M | 7.62M | 6.75M | 7.11M | 14.87M | 13.78M | 9.01M | 7.19M |
| Other Expenses | 0.00 | 0.00 | 0.00 | -674.00K | 27.88M | 24.60M | 23.76M | 48.24M | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 22.38M | 20.16M | 26.28M | 17.47M | 27.88M | 24.60M | 23.76M | 46.57M | 59.75M | 62.00M | 46.23M |
| Cost & Expenses | 22.38M | 20.16M | 26.28M | 17.47M | 27.88M | 24.60M | 23.76M | 46.57M | 59.75M | 62.00M | 46.23M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 378.00K | 184.00K | 95.00K | 109.00K | 79.00K | 0.00 | 0.00 |
| Interest Expense | 135.00K | 5.00K | 250.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 65.00K | 102.00K | 147.00K | 348.00K | 362.00K | 373.00K | 400.00K | 377.00K | 388.00K | 429.00K | 85.00K |
| EBITDA | -22.18M | -20.16M | -26.71M | -14.72M | -2.26M | -54.45M | -23.85M | -46.08M | -59.37M | -61.57M | -46.14M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -22.38M | -20.16M | -26.28M | -17.47M | -27.88M | -24.60M | -23.76M | -46.57M | -59.75M | -62.00M | -46.23M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 136.00K | 605.00K | -577.00K | 2.41M | 25.26M | -30.22M | -495.00K | 402.00K | 79.00K | 0.00 | 0.00 |
| Income Before Tax | -22.25M | -19.56M | -26.85M | -15.07M | -2.63M | -54.82M | -24.25M | -46.46M | -59.67M | -62.00M | -46.23M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -2.42M | -1.80M | -2.13M | -1.80M | -5.44M | 29.85M | -438.00K | 1.18M | 0.00 | 0.00 | 0.00 |
| Net Income | -19.83M | -17.76M | -24.73M | -13.27M | 2.81M | -54.82M | -23.81M | -46.46M | -59.67M | -62.00M | -46.23M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -2.08 | -1.87 | -3.17 | -2.95 | 0.65 | -21.11 | -23.72 | -56.81 | -5.01 | -4.80 | -3.58 |
| EPS Diluted | -2.08 | -1.87 | -3.17 | -2.95 | 0.65 | -21.11 | -23.72 | -56.81 | -5.01 | -4.80 | -3.58 |
| Weighted Avg Shares Out | 9.55M | 9.50M | 7.80M | 4.50M | 4.34M | 2.60M | 1.00M | 817.85K | 11.91M | 12.91M | 12.91M |
| Weighted Avg Shares Out (Dil) | 9.55M | 9.50M | 7.80M | 4.50M | 4.34M | 2.60M | 1.00M | 817.85K | 11.91M | 12.91M | 12.91M |
5 Hot Penny Stocks Exploding After News This Week
Bellerophon (BLPH) Receives FDA Acceptance to Reduce Study Size
Bellerophon to Present at the H.C. Wainwright BioConnect 2022 Conference
Bellerophon Therapeutics Stock (BLPH): Why The Price Jumped
These Biotech Penny Stocks Exploded Today, Here's Why
Bellerophon Therapeutics (BLPH) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
Bellerophon to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
Why Entera Bio, Orphazyme, Bellerophon Are Moving Today
8 Hot Biotech Penny Stocks For Your July 2021 Watch List
Bellerophon to Present at the Jefferies Virtual Healthcare Conference
Source: https://incomestatements.info
Category: Stock Reports